on BIOSYNEX (EPA:ALBIO)
BIOSYNEX postpones the publication of its 2025 annual accounts
The BIOSYNEX group, specializing in health diagnostics, announces a postponement of the publication of its annual accounts and 2025 financial report. Initially scheduled for April 22, 2026, they will now be published no later than April 30, 2026. This decision results from additional work required due to the ongoing safeguard procedure.
In parallel, first-quarter 2026 revenue will also be released on April 30. Listed on Euronext Growth Paris, BIOSYNEX generated €95.1 million in revenue in 2025. The group operates in 10 countries and employs nearly 410 people.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOSYNEX news